Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA012 in Paroxysmal Nocturnal Hemoglobinuria
NCT06848296Phase 1Active, not recruiting
- Sponsor
- BiSiRNA Therapeutics
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1 trial of VSA012 in paroxysmal nocturnal hemoglobinuria (PNH) (5 arms), sponsored by BiSiRNA Therapeutics. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs) and Preliminary efficacy. Started Apr 2025; status: active, not recruiting.
02
Drugs
VSA012
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06848296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848296.